Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester. 1995

J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
Molecular Pharmacology Section, National Institutes of Health/National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, USA.

The iodine-125 analog of the dopaminergically selective cocaine analog 3 beta-(4-iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester (RT1-121) was evaluated as a probe for the dopamine transporter in rat striatum. Saturation and kinetic studies indicated that [125I]RTI-121 binds to both high and low affinity components. The Kd of the high affinity component was 0.14 +/- 0.01 nM (mean +/- standard error), whereas the low affinity component demonstrated an affinity of 1.59 +/- 0.09 nM. The corresponding numbers of striatal binding sites labeled by [125I]RTI-121 were 295 +/- 6 and 472 +/- 59 pmol/g of tissue (original wet weight), respectively. Intrastriatal injections of 6-hydroxydopamine eliminated > 90% of specific [125I]RTI-121 binding in the striatum. The pharmacological profile of specific [125I]RTI-121 binding in the rat striatum was consistent with that of the dopamine transporter. There was a strong (r = 0.98, p < 0.0001) correlation between the potencies of drugs that displaced specific [125I]RTI-121 binding and the potencies of these drugs to inhibit the uptake of [3H]dopamine. In contrast, no correlation was found for the potencies of drugs to inhibit the uptake of either [3H]norepinephrine or [3H]serotonin. Autoradiographs produced using [125I]RTI-121 demonstrated a distribution of label consistent with the distribution of dopaminergic neurons in rat brain. Because of its high affinity and high selectivity for the dopamine transporter, [125I]RTI-121 may be an extremely useful ligand for the dopamine transporter.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine

Related Publications

J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
April 1996, Nuclear medicine and biology,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
November 1997, Journal of medicinal chemistry,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
January 1995, Journal of medicinal chemistry,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
May 1997, Journal of neurochemistry,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
February 1993, Molecular pharmacology,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
May 2004, Bioorganic & medicinal chemistry letters,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
October 1996, Journal of medicinal chemistry,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
March 1995, Synapse (New York, N.Y.),
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
April 2008, Molecular pharmacology,
J W Boja, and J L Cadet, and T A Kopajtic, and J Lever, and H H Seltzman, and C D Wyrick, and A H Lewin, and P Abraham, and F I Carroll
February 1997, Synapse (New York, N.Y.),
Copied contents to your clipboard!